hrs4r
 I want to donate

JOAQUIM BOSCH BARRERA

Firma
JOAQUIM BOSCH-BARRERA
Position
Cap de Grup - R4
Group leader - R4

Projectes

Codi oficial: 2024_GECP_CMF Start date:01/12/2024 Data fi: 30/11/2026 Investigador/a principal: CLAUDIA MONTAÑES FERRER Organisme finançador: GRUPO ESPAÑOL DE CANCER DE PULMON

Publicacions

Bosch-Barrera J, Estévez-García P, Martín-Martorell P, Sabatier R, Nadal E, Sais E, Gascón P, Oaknin A, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfón J, Domènech C, Morán T

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.

LUNG CANCER, 2025, 201, 108105-108105 dx.doi.org/10.1016/j.lungcan.2025.108105
Sabaté-Ortega, J, Teixidor-Vilà, E, Sais, E, Hernandez-Martínez, A, Montañés-Ferrer, C, Coma, N, Polonio-Alcalá, E, Pineda, V, Bosch-Barrera, J

Cardiovascular toxicity induced by immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis of observational studies

Frontiers in oncology, 2025, 15 dx.doi.org/10.3389/fonc.2025.1528950
López, J, Llop-Hernández, A, Verdura, S, Serrano-Hervás, E, Martinez-Balibrea, E, Bosch-Barrera, J, Teixidor, E, López-Bonet, E, Martin-Castillo, B, Sardanyés, J, Alarcón, T, Lupu, R, Cuyàs, E, Menendez, JA

Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies

Cell Death Discovery, 2025, 11, 91-91 dx.doi.org/10.1038/s41420-025-02379-y
Chouaid C, Grossi F, Ta Thanh Minh C, Raymond R, Bosch-Barrera J

Pooled analysis of oral vinorelbine as single agents in patients with advanced NSCLC.

Lung Cancer Management, 2025, 14, 2477418-2477418 dx.doi.org/10.1080/17581966.2025.2477418
Bilionis I, Fernandez Luque L, Ponce Aix S, Bosch-Barrera J, Arnaiz P, Flores A

Data-Driven Assessment of Lung Cancer Patients Using Performance Status and Wearable Device Metrics.

Studies in Health Technology and Informatics, 2025, 323, 184-188 dx.doi.org/10.3233/SHTI250074
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Prelaj A, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar Nana F, Ponce S, Albarrán-Artahona V, Dal Maso A, Spotti M, Mielgo X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier JB, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Mezquita L, Planchard D

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

CLINICAL LUNG CANCER, 2024, 25 dx.doi.org/10.1016/j.cllc.2023.11.007
Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Trigo JM, Rodríguez-Abreu D, Estival A, Carcereny E, Cucurull M, López Castro R, Medina A, García Campelo R, Cordeiro González P, Sánchez-Gastaldo A, Bosch-Barrera J, Massutí B, Dómine M, Camps C, Ortega AL, Sánchez-Hernández A, Guirado Risueño M, Del Barco Morillo E, Garrido Fernández A, Provencio M

Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

ARCHIVOS DE BRONCONEUMOLOGIA, 2024, 60, 88-94 dx.doi.org/10.1016/j.arbres.2023.12.005
Rodriguez-Abreu D, Bosch-Barrera J, Gray JE, Ahn MJ, Johnson M, Yu X, Mohammad S, Chen X, Todd T, Kim J, Reck M

STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations

CLINICAL LUNG CANCER, 2024, 25, 274-279 dx.doi.org/10.1016/j.cllc.2023.12.010
Verdura S, Encinar JA, Gratchev A, Llop-Hernández À, López J, Serrano-Hervás E, Teixidor E, López-Bonet E, Martin-Castillo B, Micol V, Bosch-Barrera J, Cuyàs E, Menendez JA

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Phytomedicine, 2024, 128, 155493-155493 dx.doi.org/10.1016/j.phymed.2024.155493
Ospina AV, Bolufer Nadal S, Campo-Cañaveral de la Cruz JL, González Larriba JL, Macía Vidueira I, Massutí Sureda B, Nadal E, Trancho FH, Álvarez Kindelán A, Del Barco Morillo E, Bernabé Caro R, Bosch Barrera J, Calvo de Juan V, Casal Rubio J, de Castro J, Cilleruelo Ramos Á, Cobo Dols M, Dómine Gómez M, Figueroa Almánzar S, Garcia Campelo R, Insa Mollá A, Jarabo Sarceda JR, Jiménez Maestre U, López Castro R, Majem M, Martinez-Marti A, Martínez Téllez E, Sánchez Lorente D, Provencio M

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26, 1647-1663 dx.doi.org/10.1007/s12094-024-03382-y

Propietat intel·lectual

Joaquim Bosch Barrera

MEANS FOR PREVENTING AND TREATING BRAIN METASTASIS

Número de publicació: EP20170382891 Data de publicació: 2019-06-26

Formulari de contacte

About IDIBGI!

menu